Skip to main content

Smith Stan's Form 4 filing

MAIA Biotechnology, Inc. (MAIA) · filed Nov 26, 2025

Accession no.
0001878313-25-000045
Filed
Nov 26, 2025
Trade date
Nov 24-25, 2025
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market purchases total $24.6K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Smith StanCIK 0001913199Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 24, 2025Common StockPPurchaseAcquired+10,000$0.99F1+$9,9001,334,289Indirect
Nov 25, 2025Common StockPPurchaseAcquired+15,000$0.98F3+$14,7001,349,289Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9675 to $0.9899, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F3

The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9550 to $1.05, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)